title: [Protective effect of N-stearoylethanolamine in suspension and in nanocomposite complex in the organs of mice with the Lewis carcinoma under doxorubicin intoxication administration].
abstract: The antioxidant effects of N-stearoylethanolamine (NSE) in the nanocomplex composition and in suspension are shown on the model of intoxication by doxorubicin in conditions of development of the Lewis carcinoma in the heart, kidneys and liver tissue and in the blood plasma of female mice. The NSE suspension reduces the level of urea in the blood plasma of mice with the Lewis carcinoma, which growth was revealed as a result of introduction of doxorubicin. Under introduction of nanocomplex the amount of urea remains at the level of that in the intact mice. In the blood plasma of mice with the Lewis carcinoma the NSE suspension and nanocomplex reduce activity of aspartate aminotransferase, the basic marker of necrosis of the heart tissue, growth of which was caused by the tumour development. Doxorubicinum increases activity of alanine aminotransferase, the marker of the liver lesion; introduction of NSE in the nanocomplex composition prevents the growth of the enzyme activity. N-stearoylethanolamine, both in the nanocomplex and in suspension, modulates activity of enzymes of antioxidantive protection of the heart, kidney and liver tissue of mice with the Lewis carcinoma.
authors.forename: Ie A
authors.initials: IeA
authors.lastname: Hudz'
authors.forename: N M
authors.initials: NM
authors.lastname: Hula
authors.forename: T O
authors.initials: TO
authors.lastname: Khmel'
authors.forename: T M
authors.initials: TM
authors.lastname: Horid'ko
authors.forename: Iu M
authors.initials: IuM
authors.lastname: Bashta
authors.forename: R R
authors.initials: RR
authors.lastname: Panchuk
authors.forename: R S
authors.initials: RS
authors.lastname: Stoĭka
authors.forename: A O
authors.initials: AO
authors.lastname: Riabtseva
authors.forename: O S
authors.initials: OS
authors.lastname: Zaichenko
mesh_terms: D000410:Alanine Transaminase / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000201:enzymology; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D004337:Drug Carriers / Q000008:administration & dosage; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006321:Heart / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000201:enzymology; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D051379:Mice; D053761:Nanocomposites / Q000008:administration & dosage; D013229:Stearic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D014508:Urea / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D015415:Biomarkers; D004337:Drug Carriers; D004983:Ethanolamines; C408368:N-stearoylethanolamine; D013229:Stearic Acids; D004317:Doxorubicin; D014508:Urea; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase